These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 26811022)

  • 1. Impact of daily number of urgency urinary incontinence episodes on overactive bladder patient reported outcomes.
    Angulo JC; Brenes FJ; Lizarraga I; Rejas J; Trillo S; Ochayta D; Arumi D
    Actas Urol Esp; 2016 Apr; 40(3):173-82. PubMed ID: 26811022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of hyperactive bladder severity on healthcare utilization and labor productivity.
    Angulo JC; Brenes FJ; Ochayta D; Lizarraga I; Arumí D; Trillo S; Rejas J
    Actas Urol Esp; 2014 May; 38(4):249-56. PubMed ID: 24462234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical evaluation of the overactive bladder and urgency urinary incontinence association with obstructive sleep apnea syndrome in a relatively young adult male population.
    Tuncer M; Yazici O; Kafkasli A; Sabuncu K; Salepci B; Narter F; Gungor GA; Yucetas U
    Neurourol Urodyn; 2017 Sep; 36(7):1804-1808. PubMed ID: 27921319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychometric validation of the OAB-V8 and OAB-V3 scales for the screening of patients with probable overactive bladder in the Spanish population].
    Brenes FJ; Angulo JC; Ochayta D; Rejas J; Arumí D; Cañadas A; Lizarraga I
    Med Clin (Barc); 2014 Dec; 143(12):521-9. PubMed ID: 24725856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and urodynamic impact of detrusor overactivity in women with overactive bladder.
    Jiménez-Cidre MA; López-Fando L; Mora AM;
    Actas Urol Esp (Engl Ed); 2019 Jun; 43(5):221-227. PubMed ID: 30862379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome.
    Chung SD; Liao CH; Chen YC; Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics, beliefs, and coping strategies among older patients with overactive bladder.
    Blasco P; Valdivia MI; Oña MR; Roset M; Mora AM; Hernández M
    Neurourol Urodyn; 2017 Mar; 36(3):774-779. PubMed ID: 27120009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder.
    Jimenez-Cidre M; Costa P; Ng-Mak D; Sahai A; Degboe A; Smith CP; Tsai K; Herschorn S
    Curr Med Res Opin; 2014 Aug; 30(8):1557-64. PubMed ID: 24762033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study.
    Vaughan CP; Johnson TM; Ala-Lipasti MA; Cartwright R; Tammela TL; Taari K; Auvinen A; Tikkinen KA
    Eur Urol; 2011 Apr; 59(4):629-36. PubMed ID: 21306820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.